#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #antibody drug conjugates

ADC Therapeutics to Present at Key Investor Conferences This November

ADC Therapeutics SA, a leader in the development of antibody drug conjugates (ADCs), has exciting plans for November. The company, which is publicly traded on the NYSE under the symbol ADCT, announced its participation in three significant investor conferences aimed at showcasing its innovative approaches and latest advancements.

Conference Details

1. Stephens Biotechnology Virtual Fireside Chat

Date: November 3, 2025
Time: 12:00 PM ET
Speaker: Ameet Mallik, CEO
Format: Virtual
This virtual chat will provide a platform for Ameet Mallik to discuss the company’s recent progress and future direction. No replay will be available for this session, so attending live is essential for stakeholders.

2. Guggenheim Second Annual Healthcare Innovation Conference

Date: November 11, 2025
Time: 1:30 PM ET
Speaker: Ameet Mallik, CEO
Location: Boston, MA
To join the webcast, interested parties can click here. This conference aims to gather healthcare innovation leaders and will provide a valuable setting for discussions on the latest in the biopharmaceutical sector.

3. Jefferies Global Healthcare Conference

Date: November 19, 2025
Time: 12:30 PM GMT
Speaker: Ameet Mallik, CEO
Location: London, England
Registration for the webcast is also available via a link on ADC Therapeutics’ investor relations page. Like the prior events, a replay will be accessible for about 30 days following the conference.

ADC Innovations in Focus

Amid these presentations, ADC Therapeutics continues to make strides in the field of ADCs, notably with its flagship product, ZYNLONTA (loncastuximab tesirine-lpyl). This innovative therapy has received accelerated approval from the FDA and conditional approval from the European Commission for treating patients with relapsed or refractory diffuse large B-cell lymphoma. Furthermore, ZYNLONTA is currently being explored in combination with other treatment options and in earlier lines of therapy.

Beyond ZYNLONTA, ADC Therapeutics is advancing efforts related to a next-generation PSMA-targeting ADC, which incorporates a unique exatecan-based payload accompanied by a novel hydrophilic linker. This development highlights the company's commitment to enhancing treatment modalities for various cancers and offers a glimpse into the future direction of their research.

About ADC Therapeutics

Founded and headquartered in Lausanne, Switzerland, ADC Therapeutics operates in London and New Jersey and is dedicated to pioneering advancements in ADC technology. The company's focus spans from clinical studies through to manufacturing and commercialization, emphasizing the need for specialized capabilities in their operations. They aim to revolutionize drug delivery systems, making significant improvements in patient care through targeted therapies.

The upcoming investor conferences represent a crucial opportunity for ADC Therapeutics to connect with stakeholders and investors, discussing not just their current successes but also their ambitious future plans. As the landscape of biopharmaceuticals evolves, ADC Therapeutics stands as a key player, eager to share its journey and innovations with the investment community.

For those wishing to stay updated on these events and ADC Therapeutics' advancements, further details can be found on their official website or through their LinkedIn page.